Advertisement

Lovastatin

  • Jian Ying
  • Li-Da Du
  • Guan-Hua Du
Chapter

Abstract

Lovastatin exists in red yeast rice, post-fermented pu-erh tea, oyster mushroom, and different varieties of fungi. It is used to treat dyslipidemia, prevent cardiovascular disease, or combined with dietary interventions. However, it is not effective in treatment of receptor-negative homozygous familial hypercholesterolemia. Lovastatin was originally known as an HMG-CoA reductase inhibitor, thus reducing cholesterol biosynthesis; more complicated mechanism of actions were discovered later. Pharmaceutical preparation strategies are needed to improve the absorption and bioavailability of lovastatin. Lovastatin can lead to drug-drug interactions and several adverse reactions though. Chemical structure modifications led to series of new statins, one of which has been list in the best-selling drugs in the history of pharmaceuticals.

Keywords

Lovastatin Red yeast rice Cholesterol HMG-CoA reductase Dyslipidemia 

References

  1. 1.
    Nguyen T, Karl M, Santini A. Red yeast rice. Foods. 2017;6(3):E19.CrossRefGoogle Scholar
  2. 2.
    Zhao ZJ, Pan YZ, Liu QJ, et al. Exposure assessment of lovastatin in Pu-erh tea. Int J Food Microbiol. 2013;164(1):26–31.CrossRefGoogle Scholar
  3. 3.
    Gunde-Cimerman N, Cimerman A. Pleurotus fruiting bodies contain the inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase-lovastatin. Exp Mycol. 1995;19(1):1–6.CrossRefGoogle Scholar
  4. 4.
    Goswami SVA, Bhunia B, Mandal T. A review on lovastatin and its production. J Biochem Technol. 4(1):581–7.Google Scholar
  5. 5.
    Betteridge DJ, Krone W, Reckless JP, et al. Compactin inhibits cholesterol synthesis in lymphocytes and intestinal mucosa from patients with familial hypercholesterolaemia. Lancet. 1978;2(8104–5):1342–3.CrossRefGoogle Scholar
  6. 6.
    Endo A, Kuroda M, Tanzawa K. Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity. FEBS Lett. 1976;72(2):323–6.CrossRefGoogle Scholar
  7. 7.
    Brown AG, Smale TC, King TJ, et al. Crystal and molecular structure of compactin, a new antifungal metabolite from Penicillium brevicompactum. J Chem Soc Perkin. 1976;1(11):1165–70.CrossRefGoogle Scholar
  8. 8.
    Ma PT, Gil G, Sudhof TC, et al. Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits. Proc Natl Acad Sci U S A. 1986;83(21):8370–4.CrossRefGoogle Scholar
  9. 9.
    Endo A. Monacolin K, a new hypocholesterolemic agent that specifically inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase. J Antibiot (Tokyo). 1980;33(3):334–6.CrossRefGoogle Scholar
  10. 10.
    Brown MS, Dana SE, Goldstein JL. Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts by lipoproteins. Proc Natl Acad Sci U S A. 1973;70(7):2162–6.CrossRefGoogle Scholar
  11. 11.
    Brown MS, Dana SE, Goldstein JL. Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in cultured human fibroblasts. Comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia. J Biol Chem. 1974;249(3):789–96.PubMedGoogle Scholar
  12. 12.
    Vagelos PR. Are prescription drug prices high? Science. 1991;252(5009):1080–4.CrossRefGoogle Scholar
  13. 13.
    Liu J, Wang M, Peng S, et al. Effect of green tea catechins on the postprandial glycemic response to starches differing in amylose content. J Agric Food Chem. 2011;59(9):4582–8.CrossRefGoogle Scholar
  14. 14.
    Endo A. A historical perspective on the discovery of statins. Proc Jpn Acad Ser B Phys Biol Sci. 2010;86(5):484–93.CrossRefGoogle Scholar
  15. 15.
    Alberts AW. Discovery, biochemistry and biology of lovastatin. Am J Cardiol. 1988;62(15):10J–5J.CrossRefGoogle Scholar
  16. 16.
    Arad Y, Ramakrishnan R, Ginsberg HN. Effects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: evidence for reduced assembly and secretion of triglyceride-rich lipoproteins. Metabolism. 1992;41(5):487–93.CrossRefGoogle Scholar
  17. 17.
    De Denus S, Spinler SA. Early statin therapy for acute coronary syndromes. Ann Pharmacother. 2002;36(11):1749–58.CrossRefGoogle Scholar
  18. 18.
    Ray KK, Cannon CP. Optimal goals for statin use in patients with coronary artery disease. Curr Opin Cardiol. 2005;20(6):525–9.CrossRefGoogle Scholar
  19. 19.
    Zhang Y, Zhang H, Che E, et al. Development of novel mesoporous nanomatrix-supported lipid bilayers for oral sustained delivery of the water-insoluble drug, lovastatin. Colloids Surf B Biointerfaces. 2015;128:77–85.CrossRefGoogle Scholar
  20. 20.
    Uauy R, Vega GL, Grundy SM, et al. Lovastatin therapy in receptor-negative homozygous familial hypercholesterolemia: lack of effect on low-density lipoprotein concentrations or turnover. J Pediatr. 1988;113(2):387–92.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. and People's Medical Publishing House, PR of China 2018

Authors and Affiliations

  1. 1.Beijing Key Laboratory of Nutrition Health and Food SafetyCOFCO Nutrition and Health Research InstituteBeijingChina
  2. 2.School of Biomedical SciencesChinese University of Hong KongHong KongChina
  3. 3.Beijing Key Laboratory of Drug Targets Identification and Drug ScreeningCentre for Pharmaceutical Screening, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina

Personalised recommendations